http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019076423-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e98e4cf0dc95eca2399be2a66c15dd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-121 |
| filingDate | 2017-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79fc0d2c6bd0e32b50ace3b166455c29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b11c4e4367d8fcbc3b1f1409d9feeeeb |
| publicationDate | 2019-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2019076423-A1 |
| titleOfInvention | Combination therapy for proliferative diseases |
| abstract | A combination product comprising: (A) a compound of formula (I) R-L-CO—X (I) wherein R is a C 10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO 2 , said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO wherein L comprises at least one heteroatom in the backbone of the linking group; and X is an electron withdrawing group; or a salt thereof; and (B) a compound of formula (X) where R 1 is phenyl wherein said phenyl is substituted by lower alkyl unsubstituted or substituted by cyano; R 3 is lower alkyl, such as methyl; and R 4 is quinolinyl unsubstituted or substituted by halogen; or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11351127-B2 |
| priorityDate | 2016-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 122.